Dermatological applications of gene silencing RNA technology
Mobile teledermatology for skin tumour screening
Drug survival rates for tumour necrosis factor-α antagonists in psoriasis
Management of palmoplantar pustulosis: do we need to change?
Small-interfering RNA targeted at antiapoptotic mRNA increases keratinocyte sensitivity to apoptosis
Depth profiling of stratum corneum biophysical and molecular properties
Introduction of a dermatophyte polymerase chain reaction assay to the diagnostic mycology service in Scotland
Mobile teledermatology for skin tumour screening: diagnostic accuracy of clinical and dermoscopic image tele-evaluation using cellular phones
Photoprotective potential of Cordyceps polysaccharides against ultraviolet B radiation-induced DNA damage to human skin cells
Effectiveness of antimicrobial photodynamic therapy with a single treatment of RLP068/Cl in an experimental model of Staphylococcus aureus wound infection
The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes
Classification of segmental vitiligo on the face: clues for prognosis
Preliminary evidence for involvement of the tumour suppressor gene CHD5 in a family with cutaneous melanoma
Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa
Expression of tachykinins and their receptors in plaque psoriasis with pruritus
Collagen triple helix repeat containing-1 inhibits transforming growth factor-β1-induced collagen type I expression in keloid
A study of the efficacy of carbon dioxide and pigment-specific lasers in the treatment of medium-sized congenital melanocytic naevi
Abnormality of RUNX1 signal transduction in psoriatic CD34+ bone marrow cells
Perturbations of both nonregulatory and regulatory FOXP3+ T cells in patients with malignant melanoma
Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression
Primary cutaneous lymphoma: two-decade comparison in a population of 263 cases from a Swiss tertiary referral centre
Correlation between serum 25-hydroxyvitamin D levels and severity of atopic dermatitis in children
A randomized, multicentre study of directed daylight exposure times of 1½ vs. 2½ h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp
Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris
Primitive erythropoiesis in infantile haemangioma
Juvenile psoriasis in European and Asian children: similarities and differences
Late-onset inversa recessive dystrophic epidermolysis bullosa caused by glycine substitutions in collagen type VII
Successful treatment of classic Kaposi sarcoma with low-dose intramuscular immunoglobulins
A dermal equivalent can be developed from fibroblast culture by means of a high concentration of serum
Livedoid vasculopathy secondary to high levels of lipoprotein(a)
Mutations in two genes on chromosome 13 resulting in a complex hair and skin phenotype due to two rare genodermatoses: KLICK and autosomal recessive woolly hair/hypotrichosis simplex
Generalized cowpox infection in a patient with Darier disease
Does HLA-G prevent tissue destruction in psoriasis?
Biologic-induced urticaria due to polysorbate 80: usefulness of prick test
Rhodotorula mucilaginosa infection in Li–Fraumeni-like syndrome: a new pathogen in folliculitis
Reflectance confocal microscopy can differentiate dermoscopic white dots of the scalp between sweat gland ducts or follicular infundibulum
Acute porphyrias: neurological manifestations and their pathogenesis : L01
Optimizing porphyria diagnostics with emphasis on pre-analytical, analytical and postanalytical aspects : L02
Erythropoietic protoporphyria: a multifaceted, multigene, multiorgan disease : L03
Intracellular compartmentalization of uroporphyrinogen and uroporphyrin : L04
Evolving therapies for porphyria : L05
Gene therapy of genetic diseases: difficulties, failures and successes : L06
Tetrapyrroles as a guidepost for solar energy conversion : L08
Acute intermittent porphyria: a severely affected knock-in mouse that mimics the human homozygous dominant phenotype : O01
Renal failure affects the enzymatic activities of the three-first steps in hepatic haem biosynthesis in the AIP mouse during a biochemical induced attack : O02
Metabolic modifications in the AIP mouse model treated by chronic haem administration : O03
Psychosocial aspects of predictive genetic testing for acute intermittent porphyria in minors : O04
An unusual case of porphyric neuropathy with atypical clinical and electrodiagnostic features : O05cc
Homecare delivery of haem arginate in acute porphyria : O06cc
Neurological manifestations in acute porphyrias: review and follow-up of 54 Brazilian patients : O07cc
Referral of patients to a porphyria clinic : O08cc
Re-evaluation of the diagnosis of acute porphyria in relatives of King George III with special reference to King James VI/I : O09
The British and Irish Porphyria Network: a collaborative for the development and dissemination of best clinical and laboratory practice : O10
Activities of specialist porphyria centres 2005–2008 : O11
Clinical and biochemical findings in 139 patients with porphyria : O12
The EPNET project to improve drug information for patients with an acute porphyria: the current role of clinical drug reporting : O13
Simultaneous presence of acute intermittent porphyria and familial Mediterranean fever in a Turkish female patient : O15cc
Excess risk of adverse pregnancy outcomes in women with porphyria: a population-based cohort study : O16
Erythropoietic protoporphyria in Denmark: demographic, biochemical and genetic characteristics : O17
Iron availability modulates the IVS3–48C/T-mediated aberrant splicing of ferrochelatase : O18
Investigation of ferrochelatase mRNA in ‘mutation-negative’ erythropoietic protoporphyria patients : O19
Liver transplantation for erythropoietic protoporphyria in Europe : O20
Erythroid mosaicism: a common feature in X-linked dominant erythropoietic protoporphyria : O21
X-linked dominant protoporphyria in the U.K. : O22
Isonicotinylhydrazine lowers protoporphyrin levels in a mouse model of erythropoietic protoporphyria : O23
Comparison of phlebotomy and low-dose hydroxychloroquine in the treatment of porphyria cutanea tarda: a prospective randomized study : O24
Proposed management algorithm for congenital erythropoietic porphyria : O25
ALAS2 gain of function mutation in a patient with congenital erythropoietic porphyria : O26cc
A randomized phase III trial of afamelanotide (Scenesse®), an agonistic α-melanocyte stimulating hormone analogue in the treatment of protoporphyria- induced phototoxicity : O27
Liver transplantation in acute intermittent porphyria provides novel insights into the pathogenesis of acute attacks : O28
Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria : O29
Toxicology and liver transduction efficacy evaluation of a recombinant adeno-associated viral vector in nonhuman primates as a potential treatment for acute intermittent porphyria : O30
AIPGENE: augmenting porphobilinogen deaminase expression in the liver as a novel gene therapy for acute intermittent porphyria : O31
Elucidating the kinetic mechanism and increased activity of 5-aminolaevulinate synthase in X-linked dominant protoporphyria : O32
Characterization of the flavin adenosine dinucleotide binding region of Myxococcus xanthus protoporphyrinogen oxidase : O33
Mitoferrin 1- iron delivery for heme synthesis : O34
Insulin downregulates ALAS1 expression in human hepatocytes : O36
A 7-bp duplication in PBGD caused acute intermittent porphyria in an Argentinian family : P01
Identification of a mutation in the protoporphyrinogen oxidase gene in a black South African with variegate porphyria : P02
Functional associations of genetic variants involved in the clinical manifestation of erythropoietic protoporphyria in Argentina : P03
Distribution study of the frequent p.G111R mutation in the Argentinian population : P04
Safety and efficacy of an agonistic α-melanocyte stimulating hormone analogue, afamelanotide (Scenesse®), in treating patients with erythropoietic protoporphyria for 2·5 consecutive years : P05
Novel variants in ATP-binding cassette protein 3 may affect clinical outcome in inherited hepatic porphyrias : P06
Hereditary haemochromatosis and porphyria cutanea tarda in Argentina : P07
The Welsh Medicines Information Centre porphyria information service : P08
New social networking site for patients with erythropoietic porphyria: report of early success and future plans : P09
Acute intermittent porphyria: a reversible cause of cachexia : P10
X-linked sideroblastic anaemia and ataxia: protoporphyrin analysis in erythrocytes as a diagnostic tool : P11
First case of heteroallelic homozygous dominant acute intermittent porphyria in Argentina : P12
Development of a proteomic approach to characterize murine biological markers of acute intermittent porphyria : P13
Haematin therapy in new cases of acute intermittent porphyria in the Argentine population : P14
Variegate porphyria in Argentina: clinical and molecular analysis : P15
Characterization of missense mutations in Argentinian patients with variegate porphyria : P16
Endogenously generated protoporphyrin IX in drug-resistant and sensitive murine leukaemia cells : P17
Molecular analysis of the porphobilinogen deaminase gene in 32 German families with acute intermittent porphyria: common ancestral origin of a recurrent mutation : P18
Congenital erythropoietic porphyria due to coinheritance of GATA1 and UROS gene mutations : P19
Acute intermittent porphyria: characterization of the molecular basis : P20
Impact of two novel mutations found in the hydroxymethylbilane synthase gene involved in acute intermittent porphyria : P21
Epidemiological study of the Danish acute intermittent porphyria population : P22
Renal handling of haem and iron in chronic haemolysis: recent concept : P23
Identification of susceptibility loci to erythrocyte protoporphyrin accumulation and to cholestasis in a mouse model of erythropoietic protoporphyria : P24
Stability of porphobilinogen and porphyrin in urine subjected to freeze/thawing : P25
Saliva DNA testing for acute porphyria : P26
Development of Welsh standards for the laboratory investigation of porphyria : P27
Routine follow-up of porphyria patients : P28
Potentiation of photodynamic therapy in bladder cells with the natural flavonoid silybin : P29
Cell adhesion mechanisms involved in resistance to photodynamic therapy of Ras-expressing tumours : P30
Porphyria cutanea tarda: a case series and review of practice in a tertiary U.K. centre : P31
Congenital erythropoietic porphyria in pregnancy : P32
Decreased glucose uptake in the primary somatosensorial cortex in the brain of female mice with acute intermittent porphyria : P33
AIP, it's the real thing : P34
Two unusual case reports of acute intermittent porphyria presenting in young females : P35
Cytochrome P450 CYP1A2 genotyping is useless in follow-up of patients with porphyria cutanea tarda : P36
Report of two patients with familial porphyria cutanea tarda : P37
Silyl nitronate 1,3-dipolar cycloaddition reactions with meso-tetraarylporphyrins : P38
Normalization of erythrocyte porphyrin in a woman with erythropoietic protoporphyria within two pregnancies : P39
Analysis of 23 case reports of erythropoietic protoporphyria in China : P40
Impact of research on routine clinical practice for patients with erythropoietic protoporphyria: a case series from a tertiary referral centre : P41
Porphyria cutanea tarda mimicking scleroderma : P42
Direct fluorometric assay for zinc protoporphyrin IX in whole blood : P43
X-linked dominant protoporphyria due to a novel mutation in ALAS2 : a case report : P44
The synthesis of asymmetrical ABCD-type porphyrins : P45
Transmission distortion of human genome involves mutant allele in a family with erythropoietic protoporphyria in Argentina : P46
An unusual complication of jaundice : P47
The incidence of inherited porphyrias in Europe : P48
The clinical spectrum of cutaneous effects of the synthetic α-melanocyte stimulating hormone analogue afamelanotide : P49
Haemolytic anaemia triggers hepcidin repression and overrides the iron signalling in uroporphyrinogen III synthase-deficient mice : P50
Identification of protoporphyrinogen oxidase gene mutations in Polish families with variegate porphyria : P51
Porphyria cutanea tarda associated with human immunodeficiency virus: identification of CYP3A5 and CYP2B6 polymorphisms : P52
Porphyrinogenic agents and the haem protein nitric oxide synthase: changes in the localization of the isoform eNOS in the liver of mice : P53
Polymorphisms of CYP2D6 in patients with porphyria cutanea tarda. Frequency of several alleles related to poor metabolizers : P54
Risk evaluation of genetic variants in the UROD gene in patients with porphyria cutanea tarda in Argentina : P55
Haplotype studies in South African and Dutch variegate porphyria families carrying the recurrent mutation p.R59W : P56
Is the ratio of urinary coproporphyrin isomers a useful diagnostic tool to differentiate various causes of hyperbilirubinaemia during childhood? : P57
Predicting drug porphyrinogenicity on theoretical grounds: can important but lacking pharmacokinetic information be obtained by contacting the pharmaceutical industry? : P58
Congenital erythropoietic porphyria in two adults with milder disease : P59
CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda : P60
Clinical validation of ferrochelatase gene (FECH) molecular analysis for the diagnosis of erythropoietic protoporphyria : P61
Four novel mutations in the protoporphyrinogen oxidase gene in Jewish families with variegate porphyria : P62
Hepatoerythropoietic porphyria: a new mutation in the UROD gene in the first Brazilian patient described : P63
Congenital erythropoietic porphyria: characterization of murine models of the severe common (C73R/C73R) and later-onset genotypes : P64
Variegate porphyria in Wales: a case series of 11 patients : P65
New directions: establishing a multidisciplinary clinic for the inherited porphyrias in Sydney, Australia : P66